AAPL   317.94 (-0.10%)
MSFT   183.25 (+1.02%)
FB   225.09 (-0.16%)
GOOGL   1,433.52 (+1.08%)
AMZN   2,442.37 (+1.72%)
NVDA   355.02 (+4.58%)
CGC   17.37 (-20.03%)
BABA   207.39 (+3.96%)
MU   47.91 (+3.10%)
GE   6.57 (-3.10%)
TSLA   835.00 (+3.62%)
AMD   53.80 (+3.98%)
T   30.86 (-0.64%)
ACB   14.08 (-8.21%)
F   5.71 (-2.39%)
GILD   77.83 (+3.33%)
DIS   117.30 (+0.47%)
NFLX   419.73 (+1.52%)
BAC   24.12 (-2.98%)
BA   145.85 (-2.65%)
AAPL   317.94 (-0.10%)
MSFT   183.25 (+1.02%)
FB   225.09 (-0.16%)
GOOGL   1,433.52 (+1.08%)
AMZN   2,442.37 (+1.72%)
NVDA   355.02 (+4.58%)
CGC   17.37 (-20.03%)
BABA   207.39 (+3.96%)
MU   47.91 (+3.10%)
GE   6.57 (-3.10%)
TSLA   835.00 (+3.62%)
AMD   53.80 (+3.98%)
T   30.86 (-0.64%)
ACB   14.08 (-8.21%)
F   5.71 (-2.39%)
GILD   77.83 (+3.33%)
DIS   117.30 (+0.47%)
NFLX   419.73 (+1.52%)
BAC   24.12 (-2.98%)
BA   145.85 (-2.65%)
AAPL   317.94 (-0.10%)
MSFT   183.25 (+1.02%)
FB   225.09 (-0.16%)
GOOGL   1,433.52 (+1.08%)
AMZN   2,442.37 (+1.72%)
NVDA   355.02 (+4.58%)
CGC   17.37 (-20.03%)
BABA   207.39 (+3.96%)
MU   47.91 (+3.10%)
GE   6.57 (-3.10%)
TSLA   835.00 (+3.62%)
AMD   53.80 (+3.98%)
T   30.86 (-0.64%)
ACB   14.08 (-8.21%)
F   5.71 (-2.39%)
GILD   77.83 (+3.33%)
DIS   117.30 (+0.47%)
NFLX   419.73 (+1.52%)
BAC   24.12 (-2.98%)
BA   145.85 (-2.65%)
AAPL   317.94 (-0.10%)
MSFT   183.25 (+1.02%)
FB   225.09 (-0.16%)
GOOGL   1,433.52 (+1.08%)
AMZN   2,442.37 (+1.72%)
NVDA   355.02 (+4.58%)
CGC   17.37 (-20.03%)
BABA   207.39 (+3.96%)
MU   47.91 (+3.10%)
GE   6.57 (-3.10%)
TSLA   835.00 (+3.62%)
AMD   53.80 (+3.98%)
T   30.86 (-0.64%)
ACB   14.08 (-8.21%)
F   5.71 (-2.39%)
GILD   77.83 (+3.33%)
DIS   117.30 (+0.47%)
NFLX   419.73 (+1.52%)
BAC   24.12 (-2.98%)
BA   145.85 (-2.65%)
Log in

LON:NFXNuformix Share Price, Forecast & News

GBX 4.30
-0.25 (-5.49 %)
(As of 05/29/2020 04:00 PM ET)
Add
Compare
Today's Range
4.22
Now: GBX 4.30
4.64
50-Day Range
4.10
MA: GBX 5.15
6.60
52-Week Range
3.33
Now: GBX 4.30
14.89
Volume3.71 million shs
Average Volume1.13 million shs
Market Capitalization£21.08 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Nuformix plc develops pharmaceutical products using its cocrystal technology in the United Kingdom. Its lead programs include NXP001, which is used for oncology supportive care; and NXP002 for use in the treatment of fibrosis. The company is also developing NXP003, which is under the pre-clinical stage for the treatment of anti-inflammatory diseases. Nuformix plc was founded in 2008 and is headquartered in Cambridge, the United Kingdom.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.50 out of 5 stars


Industry, Sector and Symbol

Industry Biotechnology
Sub-IndustryN/A
SectorMedical
CUSIPN/A
CIKN/A
Phone44 1223 423 667

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales£535,000.00
Book ValueGBX 0.80 per share

Profitability

Miscellaneous

Employees3
Market Cap£21.08 million
Next Earnings DateN/A
OptionableOptionable

Receive NFX News and Ratings via Email

Sign-up to receive the latest news and ratings for NFX and its competitors with MarketBeat's FREE daily newsletter.

Nuformix (LON:NFX) Frequently Asked Questions

How has Nuformix's stock been impacted by COVID-19 (Coronavirus)?

Nuformix's stock was trading at GBX 5.50 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, NFX stock has decreased by 21.8% and is now trading at GBX 4.30. View which stocks have been most impacted by Coronavirus.

Has Nuformix been receiving favorable news coverage?

Media coverage about NFX stock has been trending extremely negative this week, InfoTrie Sentiment reports. The research firm ranks the sentiment of media coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Nuformix earned a news sentiment score of -4.0 on InfoTrie's scale. They also assigned news headlines about the company a news buzz of 1.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the stock's share price in the near term. View the latest news aboutNuformix.

Who are some of Nuformix's key competitors?

What other stocks do shareholders of Nuformix own?

Who are Nuformix's key executives?

Nuformix's management team includes the following people:
  • Dr. Daniel John Gooding, CEO & Director (Age 45)
  • Dr. Joanne M. Holland, Chief Scientific Officer & Director (Age 44)

What is Nuformix's stock symbol?

Nuformix trades on the London Stock Exchange (LON) under the ticker symbol "NFX."

How do I buy shares of Nuformix?

Shares of NFX and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

What is Nuformix's stock price today?

One share of NFX stock can currently be purchased for approximately GBX 4.30.

How big of a company is Nuformix?

Nuformix has a market capitalization of £21.08 million and generates £535,000.00 in revenue each year. Nuformix employs 3 workers across the globe.

What is Nuformix's official website?

The official website for Nuformix is www.levrett.com.

How can I contact Nuformix?

Nuformix's mailing address is Ste 31 Second Fl, 107 Cheapside, LONDON, EC2V 6DN, United Kingdom. The company can be reached via phone at 44 1223 423 667.

This page was last updated on 5/29/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.